Genetic testing for better prostate cancer screening in Veterans
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS): A Pragmatic Trial of Precision Prostate Cancer Screening
NA · VA Office of Research and Development · NCT05926102
This study is testing a genetic test to see if it can help identify male Veterans who are at high risk for serious prostate cancer, aiming to reduce unnecessary biopsies for those at low risk.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 5000 (estimated) |
| Ages | 55 Years to 69 Years |
| Sex | Male |
| Sponsor | VA Office of Research and Development (fed) |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT05926102 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of a genetic test in identifying male Veterans at high risk for significant prostate cancer. By comparing this precision screening approach to usual care, the study aims to reduce unnecessary biopsies in men who are at low risk for the disease. The research addresses the limitations of current screening methods, which often lead to overdiagnosis and overtreatment. The goal is to enhance prostate cancer screening strategies within the Veterans Health Administration.
Who should consider this trial
Good fit: Ideal candidates are male Veterans aged 55-69 who receive regular VA care.
Not a fit: Patients with a personal history of prostate cancer or prior prostate interventions will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate prostate cancer screenings, reducing unnecessary procedures and improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using genetic testing for cancer risk assessment, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * baseline age 55-69 years * receipt of regular VA care * Veteran status Exclusion Criteria: * personal history of prostate cancer * prior prostate biopsy, prostatectomy, or prostate MRI * known carrier status of rare variant associated with cancer syndrome
Where this trial is running
Boston, Massachusetts
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA — Boston, Massachusetts, United States (RECRUITING)
Study contacts
- Principal investigator: Jason L Vassy, MD MPH — VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
- Study coordinator: Charles A Brunette, PhD
- Email: charles.brunette@va.gov
- Phone: (857) 364-6324
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prostate Cancer, early detection of cancer, prostatic neoplasms, polygenic risk scores, family health history